Good day. Welcome to the Coloplast Q1 2017/2018 conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. Lars Rasmussen, CEO. Please go ahead, sir.
Thank you very much. Good afternoon, welcome to our Q1 2017/2018 conference call. My name is Lars Rasmussen. I am CEO of Coloplast, and I'm joined by CFO Anders Lonning-Skovgaard, and our investor relations team. We will start with a short presentation by Anders and myself, we will open up for questions. Please turn to slide number three. Today, Coloplast delivered yet another strong quarter with 8% organic growth, which I'm very pleased with. Despite last year's low comparison based in Q1 in the U.S., we can see solid underlying performance across most parts of the business, and we continue to take market shares. I remain excited about the prospects of the U.S. business. The underlying demand for our products is solid, and we are clearly driving the shift in the market towards more advanced hydrophilic catheters.
Today, I'm also happy to announce that we have kicked off the launch of a new ostomy appliance within our SenSura Mio portfolio. The product is called SenSura Mio Concave, and it is the first product on the market specifically designed for people with hernias and curves. The product has been pre-launched in seven markets, and the feedback from nurses is positive. In November, we communicated a new long-term guidance to the market based on an ambition to accelerate our organic investments to drive further growth. In Q1, we have increased our investments in the U.S., several emerging markets, Urocare, and Comfort Medical. We have also decided to establish our own organization and direct sales in ostomy and continence care in Portugal. Linked to our strategic update in November, we recently completed the acquisition of a small direct-to-consumer business in France to strengthen our service offering towards consumers.
Our results are negatively impacted by a significant healthcare reform in Greece, which had a particularly large negative impact on our Wound Care division this quarter. For the year, we expect Wound Care to grow in line with the market, driven by improving momentum in emerging markets. We also saw a significant negative currency impact in the quarter. Our organic revenue guidance for 2017/2018 is unchanged, with a growth of around 7%, whereas our growth in Danish kroner is now 1 percentage point lower at around 5% to 6% due to the continued depreciation of the U.S. dollars against the Danish kroner. Our EBIT margin guidance is in fixed currencies, Danish kroner is unchanged at 31% to 32% and around 31% respectively. Please turn to slide number four.
Revenues grew 8% organically and 5% in Danish kroner and amounted to DKK 4 billion. In Ostomy Care, organic growth was 9%, and growth in Danish kroner was 7%. Growth continues to be driven by the SenSura Mio and Brava accessories portfolios. The SenSura Mio portfolio saw a satisfactory growth in Europe and the U.S. In particular, SenSura Mio Convex continues to contribute to growth. The SenSura and Assura portfolio growth was driven by satisfactory performance in China, Argentina and Brazil. In Continence Care, organic growth was 10%, and growth in Danish kroner was 9%. The SpeediCath ready-to-use intermittent catheters continue to drive growth, and especially the compact versions performed well. In the compact segment, we saw strong growth in the U.S., as well as satisfactory growth in U.K. and France.
We continue to see healthy growth rates in Japan, Australia, and South Korea, following the introduction of reimbursement for intermittent catheters in these markets. So far, we have seen limited impact from the expiry of the SpeediCath standard ready-to-use patents. SpeediCath Flex have now been launched in 16 markets and continues to contribute strongly to growth. Our Conveen collecting device portfolio posted slightly positive growth due to satisfactory growth in France. Finally, sales growth for Peristeen products remains satisfactory. In UroCare, organic growth was 11%, and growth in Danish kroner was 6%. The double-digit growth was primarily driven by sales of Titan penile implants and Female Pelvic Health products in the U.S. We made large investments into the U.S. implant business last year and will continue to invest this year. Our end Uro business saw satisfactory growth in Europe, in particular in France.
In Wound & Skin Care, organic growth was declined by 5%, and growth in Danish kroner declined by 9%. Organic growth for Wound Care in isolation declined by 7%. The quarter was negatively impacted by price reforms in Wound Care in Greece. This negative development was reinforced by a strong Q1 last year because of price reforms. Adjusted for Greece, Wound Care growth in the quarter was in line with the market. On a positive note, growth in the Biatain Silicone portfolio was double digits, driven by Europe and the launch of Biatain Silicone sizes and shapes. The U.S. skincare business contributed to growth in the quarter on the back of customer wins last year and during the quarter. We were successful in winning the skincare GPO contract with HealthTrust.
Contract manufacturing of Compeed contributed quite negatively to growth due to the inventory re-reductions in connection with the sale of the Compeed brand from Johnson & Johnson to HRA Pharma. We expect a pick up in momentum over the next quarters. Turning to our geographical segments, we saw organic growth of 4% in Q1 in our European markets. The growth continues to be satisfactory across the portfolio of countries driven by recent product launches. Organic revenue growth in other developed markets was 18% in Q1. The underlying growth in the U.S. in the chronic care business is strong and continues to be double digits. Revenue in emerging markets grew organically by 10% in Q1. The growth was driven by China, Argentina, and several smaller emerging markets countries, but growth was significantly negatively impacted by Greece, as explained earlier.
With this, I'll now give the word to Anders. Please turn to slide number five.
Thank you, Lars. Good afternoon, everyone. Gross profit was up by 3% to around DKK 2.7 billion. This equals a gross margin of 67% compared to 69% last year. In constant currencies, the gross margin was 68% compared to 69% last year. The gross margin was negatively impacted by the launch of new products, where the production economy is not yet fully optimized, as well as increasing depreciation levels and costs associated with the relocation of production to Hungary. On a positive note, we continue to see improvements in production efficiency at our volume sites and a positive impact from the relocation of SenSura Mio to Hungary. The distribution to sales ratio came in at 30% compared to 28% last year.
The 10% increase is in line with our newly communicated long-term guidance of increased investments to drive further growth over the next couple of years. As mentioned earlier, we approved new investment cases in Q1 across our business areas and regions. The Admin to sales ratio came in at 4% of sales on par with the recent trend. The R&D to sales ratio came in at 4% of sales in line with last year. The 14% increase in R&D cost reflects a higher general activity level. Overall, this resulted in an increase in operating profit in fixed currencies of 4% and a decline of 2% in actual currencies, corresponding to an EBIT margin of 31% in both fixed and actual currencies. Operating cash flow amounted to DKK 1 billion, compared to DKK 254 million last year.
The increase is primarily explained by higher mesh payments last year compared to this year. Total mesh payments to date amount to DKK 4.2 billion. Cash flow from investing activities was impacted by the site expansion in Nyírbátor in Hungary and capacity expansion in machines to produce new and existing products. Investments in intangible assets and property, plant, and equipment amounted to DKK 196 million for the quarter, up DKK 75 million compared to last year. Adjusted for payments made in connection with the mesh litigation and the acquisition of Comfort Medical, the free cash flow amounted to approximately DKK 947 million compared to DKK 1.4 billion last year. Adjusted for timing of tax payments, the free cash flow was in line with last year.
Our cash conversion in Q1, calculated as a 12-month trailing average, was 99%. With respect to the mesh litigation in the U.S., we have settled more than 95% of the known cases. We still view the provision as sufficient. We are in the final phase of the mesh litigation. In 2017/2018, we still expect to pay out the remaining DKK 1 billion of the DKK 5.25 billion provision. We have reviewed and analyzed the impact of the U.S. tax reform passed in December. Our view is that it will not have a material impact in the current and subsequent financial years. Finally, the board has today approved a new share buyback program of DKK 1 billion over the next two years.
The first part of the program, of DKK 500 million, will be initiated in Q2 and is expected to be completed in Q4. Please turn to slide six. Our organic revenue guidance for 2017/2018 is unchanged, with a growth of around 7%. Our growth in Danish kroner is now expected to be 1 percentage point lower at 5% to 6%, primarily due to the depreciation of the US dollar and dollar-related currencies against the Danish kroner. Our guidance still assumes a negative impact of DKK 100 million from the patent expiry on SpeediCath standard catheters. For 2017/2018, we continue to expect a negative pricing pressure of more than 1 percentage point on our top line due to healthcare reforms in Greece.
In October, price cuts of around 25% were implemented for Ostomy Care, Continence Care, and Wound Care at the distributor level. Since then, we have appealed to the Ministry of Health, hence, the actual reform outcome and impact still remains highly uncertain. We continue to assume an impact of DKK 100 million in our guidance. Aside from the impact of the patent expiry and the healthcare reforms in Greece, our guidance assumes stable underlying growth trends across our regions. The guidance in Danish kroner is significantly impacted by the depreciation of the US dollar, as well as dollar-related currencies against the Danish kroner. The currency impact is based on spot rates as of January 24th. For 2017/2018, we continue to expect an EBIT margin of 31% to 32% in constant currencies and around 31% in Danish kroner.
The EBIT margin guidance includes the impact of our assumptions around the SpeediCath patent expiry and healthcare reforms in Greece, as well as acquisitions. On our operating expenses, we expect broadly stable trends since or in 2017/2018. This year, we will invest up to 2% of sales, enhancing initiatives. Higher growth from our new product launches still means pressure on the gross margin. As previously communicated, we continue to relocate manufacturing out of Denmark to Hungary, and we will reduce the number of production workers in Denmark by additional 100 people in 2017/2018 . We expect the benefits to be absorbed by the cost of relocation and restructuring costs of approximately DKK 20 million in 2017/2018 . We expect high single-digit wage inflation in Hungary in 2017/201 8.
We also expect depreciation to increase at the same level as last year, as a consequence of the last couple of years increasing CapEx. In summary, the EBIT margin guidance is negatively impacted by healthcare reforms in Greece, as well as the patent expiry. Despite the downward pressure on the EBIT margin from these factors, we are in accordance with our new long-term guidance, accelerating our commercial investments to drive growth. We currently expect our net financials to end the financial year 2017/2018 at +25 million DKK, primarily due to hedging gains on the US dollar and the British pound. CapEx guidance for 2017/2018 is expected to be around 700 million DKK, and is driven particular by investments in more capacity for new and existing products, as well as the Nyírbátor expansion, which is expected to be operational during the first half of 2017/2018.
Finally, our effective tax rate is expected to be around 23%. This concludes our presentation. Thank you very much. Operator, we are ready to take questions.
Thank you. If you would like to ask a question, please signal by pressing star one on your telephone keypad. If you're using a speakerphone, please make sure your mute function is turned off to allow your signal to reach our equipment. Again, press star one to ask a question. Our first question comes from Lisa Clive from Bernstein. Please go ahead. Your line is open.
Hi, good afternoon. Three questions. First, what was the issue in China for Wound & Skin Care? I'd just like to know whether this is a Coloplast specific issue or represents a broader market slowdown in this category. Second, if you could just give us a global figure for Wound Care growth ex Greece. Third, on the Greece impact, from the commentary in the press release, it sounds like Wound Care was the really the main division that was hit, but you do continue to expect it to hit all the businesses. Is there a delay in the impact on Ostomy and Continence Care? Will that come through in Q2, or is it just a much smaller proportion of the business for those two divisions, and so it's not really as material?
Take the last one again. What was that?
On Greece, it was a Wound Care issue, or rather, it hit Wound Care rather severely, but really didn't seem to have an impact on Ostomy Care and Continence Care. Is that just because it's a much, much smaller portion of the business, or is there some sort of delay and we'll see that hit later?
Okay. All right. The issue in China on wound care basically is that we had in some hospitals there was not that much money in the last couple of months of the year. There was some holding back on purchase in some of the accounts that we have. Mind you, that as we have very strong growth in ostomy care in China, but that's an out-of-pocket market. We are very, very much selling most of our products in wound care directly to hospitals, and they purchase directly from us. I would expect that most other in the market would also have seen that if they're present in the same channel.
The Wound Care growth, if we take the Greece out of the comparison numbers, that would place us within the range of the 2% to 4%, which is the market growth as we see it right now in Wound Care, but at the lower end of the range. It does have a very significant impact. Actually, just to give you a guidance on how much this is, if you take the impact that we have seen on Greece, and then what we talked about on Compeed, those two things alone, the docks more than a full point of growth in the quarter from the business.
It's something that comes back to us, that will come back later on, because we actually expect Wound Care to grow in line with the market for the full year, and we also expect to get back to the former levels that we had on Compeed in the rest of the year. Your assumption on your last question about the impact on Wound Care from Greece, it is because it's if you take it on a, if you take the Greek sales as a total percentage of the total sales of Wound Care, it's much more influential than you will see in the other markets.
Great. Thank you very much.
If you find your question has already been answered, you may remove yourself from the queue by pressing star two. We'll now take our next question from Veronika Dubajova from Goldman Sachs. Please go ahead, your line is open.
Good afternoon, gentlemen, and thank you for taking my questions. Apologies if I missed this in the prepared remarks. I joined the call a little bit later, but I just want to understand, I guess, at what point in time, if you don't hear back from the government or if the appeal is unsuccessful, will you resume the normal course of business in Greece? As we think about this DKK 200 million of revenues that you generate, or DKK 250 million in Greece in totality, just what are you thinking? You know, at what point in time are we gonna end up below the DKK 100 million that you've guided for, and at what's the probability that we end up at the DKK 100 million, I guess, is maybe a fair question to, a fair way to ask the question.
My second question is on the full year guidance. If I look at the margin this quarter, it's certainly fallen below the 31% that you're targeting for the first year, for the full year. What would be great to understand is what are some of the levers that you have in the business to get you to 31% for the year? What's your degree of confidence with that? Thank you.
Yeah. I think I'll take the first part of the question and let others have the second part of it. When it comes to Greece, it's a, it is, as you're also alluding to, a negotiation process. We are, however, getting some little bit of tailwind since we spoke last time, because of the situation in Greece, Hollister have decided to withdraw from the market, and they are no longer going to serve the market. That means that a number of the patients will have to find themselves a new supplier, so that works in a positive way.
I think that we will be able to contain the total damage in Greece within the amount that we have guided at the beginning of the year. We didn't mention it that much, but we have had a very good start. If you take the total picture on catheters and on Continence Care, because we have not really seen any impact from the expiry of the patents. All in all, the sort of the red flags that we went into the year with, we feel that we can definitely stay within them.
Yeah. In terms of your, EBIT margin question, Veronika, I'm confident that we will deliver an EBIT margin in constant currencies of the 31% to 32% level, and around a 31% level in Danish kroner. The main drivers are higher nominal sales in the coming quarters, plus that we have already included the sales and marketing investments from the Q1. I am confident that we will deliver on the EBIT margin for the full year.
So just to follow up on that, Anders, you wouldn't expect, selling and marketing to accelerate dramatically from the level that you saw in Q1?
I see that, for the Q1, our distribution cost and percentage of revenue was around 30%, and I expect that we'll be at that level for the coming quarters as well.
Okay. Okay, any comment on the gross margin that you'd make and the kind of commitment that you had hoped for it to be flat year-on-year? Does that still hold, do you think, on a full year basis?
Yeah, for the full year basis, I still assume that we will have a gross margin in fixed currencies at a flat level compared to last year. We are negatively impacted, as I said earlier, from the new launches, especially from good growth on SenSura Mio Convex. For the full year, I'm still expecting that our gross margin will be in line with last year in the constant currencies.
Fantastic. My last question is, a competitor of yours obviously has been having some issues manufacturing. If I look at your growth rate, it seems in ostomy, it seems to have picked up sequentially just a tiny little bit. Is this, you starting to see some benefits from that competitive situation or anything else going on?
That's very hard to judge where the market share gains are coming from. The majority of the growth that we are seeing is coming out of the new products that we're having and picking up new patients, and then from, also from assessments. It's very hard to say, Veronika.
Okay, understood. Thank you very much.
Our next question comes from Annette Lykke from Handelsbanken. Please go ahead. Your line is open.
Thank you so much. My first question is on the Wound Care, where you said that, adjusted the for the Greek reform, you were probably in maybe 2% growth or so. It's just one and a half year ago, you had very high ambitions for this segment, with the completely different growth rates, targets. What has changed and what is needed to do just to get into, I would say, average of a Coloplast growth? That's my first question. My second question is on the Concave ostomy bags. Looks really interesting.
If we look at the incidence rate for people having hernia, it's maybe in the region of 1.5% to 2%, in average, maybe significantly higher in the ostomy area. Could you share a little bit on that? Thank you.
Yeah. So for wound care to grow in line with and more than the rest of the company, of course, you need a higher growth than what you had in the Q1 in China. But we have also been held back in the period that we talk about from a quite severe healthcare reform in France. So I expect that
Yes, last time. If it's been corrected.
That will help us.
Yeah.
Yeah. If we correct for that, then you start to get up to where the rest of Coloplast is. That's not our ambition. Our ambition is actually to grow 15% per year. In that sense, we need to grow more and we need to invest more. With the investments that we are taking right now, we are also investing to grow quite significantly, for example, in the U.S. As I mentioned in the opening remarks, we just got a contract with one of the bigger purchase organizations in the U.S., HPD.
That will, of course, help us accelerate in that part of the country going forward. We're also investing into emerging markets. It is right that we need more growth. I just have to say that flat out, of course.
You lack critical size? I mean, is it?
Yes, we lack critical size, but not to grow.
Yeah.
Not to grow, more to have the profitability that we need to have in that business area.
Any acquisitions is relevant there?
We'll definitely come back to you if the right things pops up, that's for sure. It's no secret that we're looking at what we can do to also strengthen the company in an inorganic way. As you know, we're also quite concerned that it should be value creative, so not at any price. On the Concave side, yes, the incidence of hernias is somewhat bigger when it comes to ostomy patients. This is not only hernias, it is also if you have or get an outward body shape during the course of the time when you're having an ostomy.
It is a known fact that many ostomy patients they will gain weight after surgery, and therefore, this is a real problem. What we have developed here is a problem solver, and we're also going to launch it at a price that the problem solvers are getting. We have another problem solver in the portfolio, which is, for example, concave, which is on average, sorry, convex, which is on average, sold at a 50% premium to flat appliances. That's what we're talking about.
Thank you so much.
Our next question comes from Michael Jüngling from Morgan Stanley. Please go ahead. Your line is open.
Yeah, hi, good afternoon. Three questions, please. Firstly, on the on the SpeediCath pattern expiry, can you comment on what you've seen so far in in the quarter, or if you like, year to date? Perhaps you can also comment on how many competitors you may have seen, even if they're quite small. Secondly, on U.S. tax reform, what is the main reason why you think the tax reform will not have a material impact? At the margin, is it going to be more positive or negative? Thirdly, on distribution costs, how long does the step-up in investment in the Q1 take before you start seeing an impact on sales?
Are you sort of thinking six months lag or nine months lag, or is it even a bit longer than than that? Thank you.
On the SpeediCath side, there are quite a number of competitors in the market already. Yes, we have seen new companies also being listed, not a big number. It's not really had a major impact on, or any, really any impact on the sales sales growth that we're having. It's not like we see something which we did not expect to see in the market. Maybe a little bit less than what we expected to see. If I think about, you know, what time the investments that we are taking now, what is the time for them to have an impact?
This is our Q3 where we are growing 8% organically. Actually, a lot of the things that we have done are having an impact on the growth rate in the company. The investments that we take now, I expect them to come within the time period that we have up to 2020. I can't. It's very hard for me to be very specific on whether it's in six or 9nine or 12 months period that they will come in. We are investing, and quite consciously so, investing to get short-term growth up also. It's. But I can't be more specific than that. On the tax reform, would you like to add something else?
In terms of the U.S. tax reform, today, around 80% of our taxes are paid out of Denmark. The reduction in the corporate tax rate in the U.S. is not having a significant impact on our tax rate guidance. I still believe that we will deliver a tax rate of around the 23% for this year and also for the coming years.
Okay. Briefly, a follow-up question on SpeediCath pattern. Are you surprised that some of your major competitors, let's say like ConvaTec, has not yet launched a product which is compatible on a self-lubricated basis, and therefore is the DKK 100 million that you've guided to now too high? Is the impact going to be less than DKK 100 million?
That's, that's obviously too, a little bit too early to say, but if we don't see further impact in the coming quarters, then what we see in the Q1 is definitely too high.
Great, thank you.
Our next question comes from Inês Silva, from Bank of America Merrill Lynch. Please go ahead.
Hi, thank you for taking my question. Two questions on the EBIT margins, please. First of all, on the gross margin, can you explain your path to the flat gross margin by the end of the year? I'm just asking this question because it seems like the headwinds, in the mix came from new products, but also your growth is being driven by the new launches. I just wanted to understand how is this going to not happen going forward? My second question is just on operating income. You booked, some operating income here, I was just wondering if you could give us an outlook for the full year.
The first question related to the gross margin, as I said earlier, I am expecting for the full year that it will be in line with last year. I'm expecting that we will see higher nominal sales in the coming quarters, and that will also have an impact on the gross margin. We are currently also relocating production from Denmark to Hungary, so we are moving machines from Denmark to Hungary. And I also expect that that will contribute, and finally, we are reducing the number of FTEs in Denmark as a consequence of the Innovation Excellence One program. And I also expect that that throughout the year will contribute to the gross margin development.
In terms of the other question around other income, I'm not giving you a specific. It was around the net financials? Yeah, in terms of the net financials, as I said earlier, I'm expecting for the year to have a +DKK 25 million impact on our net financials. So that's how I see it right now.
I was asking about other operating income, which you book inside the EBIT.
Other operating income, it's something I'm not specifically guiding on. We have had a patent or a patent settlement in the Q1 that impacted the Q1. I'm not giving you my full year perspective on that. That is included in my EBIT margin, the guidance of the 31% to 32% in standard currencies.
Okay, thank you.
Once again, if your question has already been answered, you may remove yourself from the queue by pressing star two. We will now take our next question from Sebastian Walker, from UBS. Please go ahead.
Hi there. Thanks for taking my questions. Just two, please. First, going back to profitability, I mean, I'm surprised, given the strong growth we saw within chronic care, that we didn't see a more positive mix impact on the margins. I was wondering if there was some kind of phasing in terms of the investments that you're planning on making this year? Any indication on timing, that would be helpful. The second one as well, if it would be great if we could get some more detail on the Portuguese reimbursement reform, I believe that caused you to make your changes there. You know, what proportion of sales is that region as well for you? Thanks very much.
In terms of the investments into our sales and marketing organization, we have initiated a number of investments already now from Q1 across the businesses. We have initiated a number of investments in the U.S., in emerging markets. We have also increased our R&D ratio. I expect that the levels we have seen in % of revenue, that will continue throughout the year. I'm also confident that we will deliver on the EBIT margin guidance. As I said earlier, I'm comfortable that we will deliver in standard currencies and EBIT margin in the level of 31% to 32%, and also around 31% in DKK. The Portuguese?
On the Portuguese side, the because of a higher reimbursement, a higher coverage, in Portugal, there is an opportunity now to remove the co-pay, which we have seen in the market. That means that market will start to work as a normal market in Ostomy Care. Then on the catheter side, there have historically been no reimbursement. That is now being changed, so there is actually a really good reimbursement there, and that is what we want to address.
We have actually earlier on, been in a similar situation, where when we started to serve the French market with catheters, there was no reimbursement, and today we have a significantly more than 50% market share in France. We have some experience on how to build a strong market share fast, and that experience we are going to bring to Portugal also. It means that the potential value of the Portuguese market have increased by factors since this change, that's also why we are establishing or have established our own organization there.
Great, thanks. Just to follow up on that, how big is Portugal today in terms of sales?
Very small.
Got it. Thank you.
Our next question comes from Patrick Wood of Citi. Please go ahead.
Perfect. Afternoon, everyone. Thank you for my questions. I have two remaining, please. The first would be in Greece. Could you give us a sense of who the other competitors on the Wound Care side are there? Is it the usual sort of collection of people within that market? Roughly, how competitive is your position versus theirs within that market? Whether you want to define that as market share or whether you sort of give a numeric ranking. The other question is on the M&A side. On the Wound Care side, again, you know, historically, it's been a bit of a problem with a lack of assets up for sale. Now it sounds like there's obviously things on the market.
I guess the question is: How many more reimbursement shocks, like the one we saw in Greece, do you think you need before you get an acceptable price for the assets that you're clearly trying to court? That'd be helpful to get a sense on timing on that sort of thing. Thank you.
You're welcome. Well, this is a very bold statement, but I say it anyways. If you look at the competitive situation in Greece, it is very different than what you see in most other markets, because there is hardly any real competition in the market. We serve Greece through a distributor who only deals with Coloplast. They have managed to get a very significant market share. That's, of course, also why it's meaningful numbers in our portfolio. Therefore, this is the impact that we see in Greece on the pricing is not due to a competitive situation which have escalated or anything else.
It is really only down to a price reform, which is driven out of the overall financial situation in Greece. Then to your second question, wound care is the biggest market we are serving. It's a market where we think that the growth rate is 2% to 4% for the time being. It's not because of a low volume growth, but it is because of price pressure in the market. We see that this market continues to be an interesting market, but it is also a very competitive market to be in. Therefore, of course, there is a limit to what kind of value you can put on a wound care target.
There is no doubt, and you can sort of assure yourself by on that statement, there is no doubt that if you get to a certain scale, it is a very profitable business area. You can look at, for example, Mölnlycke and look at their numbers. They have EBIT margins that they more or less resembles the EBIT margins that Coloplast is having. That's not nowhere near where we are for the time being with our Wound Care business because we are soft scale.
Hence the interest for us, from our side to scale that business because because it's a business with pretty nice gross margins, but the cost to serve is are quite significant, and that's the reason why scale really matters in this market. I don't know if that answers the question, but that's.
It does. It's very helpful.
One date.
Thank you very much. That's very helpful.
Welcome.
Our next question comes from Kristian Johansen of Nordea. Your line is open. Please go ahead.
Hi, this is Kristian from Nordea. I have a couple of questions. Thank you. First, on products. You previously said that you intended to introduce a new version of your SpeediCath Flex product for the U.S. market.
Yeah.
That specifically addressed the higher reimbursement Coudé category.
Yeah.
Has that been launched, and has it had any effect in this quarter?
No, it has not been launched. It will be launched in the second half. It's everything is progressing as we expected it to, and is following the plan completely.
Then secondly, on the Concave product that you are now introducing to the market, can you give us some sort of idea on what your production ramp and what your market assessment is for this product? We, of course, recall that you introduced your Convex product a couple of years ago, where you were surprised by the demand. Is there a chance of a similar situation developing here? How are you going to market with this product?
Yeah, I would almost say I hope so, because we completely blew the budget at that point in time, and had to pause the launch to build more capacity, even though we had capacity for index 200 compared to our launch forecast. This is a little bit of a different situation because there are no other similar products in the market. That means that we also have taken into consideration that we are creating a new segment within the market with this. Therefore, we don't expect to have the same kind of pickup as we saw on the Convex.
What I think is important to note here, because sometimes we tend to, of course, to be focused on this quarter and the next quarter. That is that every time a person switch from a flat appliance to one of these products, either convex or concave, the value per patient goes up by approximately 50%. That is the real underlying driver for this, because these are problem solvers.
They help people live a fuller life, and but they are also paid for in a different sense, and that's really important, in a market where values are not going up per product area, then, and a value upgrade is really important to us.
Thank you. That's helpful. Just one question for clarification. I think you mentioned to one of the first questions that Greece and Compeed had deducted around 1 percentage point of growth from your business. Is that to be understood as from the group, or how should we understand that?
That's from.
Yeah.
That's from the group numbers.
Yeah
in Q1.
Thank you.
It's just to make sure that you understand how, you know, how big the impact is.
Thank you.
The fact that we expect to come back to normal growth in both areas for the rest of the year. Actually also to gain some of the lost from the Q1.
Thank you.
Which means, we, you know, that's why I'm saying we expect to grow within the market growth for the full year in Wound Care, and we expect that Compeed will contribute with more or less what it did last year, at least.
Okay. Thank you.
Our next question comes from Yi-Dan Wang from Deutsche Bank. Please go ahead.
Thank you very much. I have several questions. I'll start with the Concave question. Just want to clarify, given that it's a new category, and presumably you would need to establish reimbursement for that, are you saying that the 50% premium that you're getting for that is from this, the work that you've done on this reimbursement work? This is essentially the first premium-priced product that is coming out of your pipeline. Then, what proportion of the patient population would you expect to convert to, or to convert to Concave? My second question is moving down the page.
In terms of the growth margin, I fully understand the constant currency indications, but can you give us what the as-reported growth margin would be if currency stays where it is, given that there is potentially decent amount of additional pressure from FX coming through? Finally, on the EBIT margin, slightly surprised that you are maintaining the 31% guidance. I suppose, mathematically, it would be 30.5% to 31.4%, would be the range that we're looking at. The surprise is really that the Lilial acquisition that you've made is dilutive. It is relatively a big one in terms of the impact on EBIT margin, and then FX has become even more negative.
just if you could reconcile, well, if you can, where along that range you would, we should be looking at, that would be helpful. Thank you.
If we let me start out with the concave, and then honestly, we'll come back to your more financial questions. I don't have a number which I want to state publicly on how many people we think would be using the concave products, but this is a new category. It means that we have to go country by country and get a reimbursement class for these products. We have, of course, gotten the first ones, but we have to establish that market by market.
It's obvious because it's also a product that's as a, you know, I named it a problem solver before, which also means that we are asking for higher payment for it. It is a product that is significantly helping out people who have what we call an outward body profile. That is many people, but I can't give you a fixed number, but it's enough people that we thought that this would be worth creating a separate category for it. It is not one of the products that we consider or that we mentioned at the first or at the capital market day that we had last year.
Those products would be even more differentiated than this one. That's not what we're talking about, but anyways, it's the same kind of thinking. It is a product that have a different clinical profile, and therefore, also a product that which we are going to ask more or higher payment for. It might take some patience in some markets, but that's how it has to be.
In regards to the two other questions, in terms of the EBIT margin, as I said earlier, we are expecting an EBIT margin Danish kroner of around 31%. You're correct, that is in the level of 30.5% to 31.5%. That's the range around 31%, and it is including our acquisition of Lilial. For the gross margin, the impact on currency in the Q1 was around 0.5%, so negative impact in the level of 0.5%. I would assume it's in that level for the full year.
Okay, let me ask the EBIT margin question a different way. Consensus has you at 31.2% at the moment. Do you think you would be, like, around that number, or do you think you can deliver that number?
so for the full year, as I said earlier.
Yes.
In constant currencies, we have a guidance of 31% to 32%, and I'm confident that we will deliver within that guidance.
Right. You have FX, which is working against you, and acquisition that's sort of against you, so but anyway, okay, I'll accept that answer. Then, just one last question on the FX. That turned out to be, sort of more negative than expected. Just wondering which of the, dollar-related currencies has shifted compared to last quarter? Our model was relatively accurate up till, Q1. Just wondering what proportion of your revenues is coming from the other basket of, dollar-related-
Yeah.
currencies.
It's a number of emerging markets currencies. It is especially the Brazilian real, the Argentinian peso, that has also the impacted us negatively.
the proportion of your revenue from that whole basket, I don't expect, you know, like, % by currency, but just in aggregate, what proportion of your revenue do they represent?
It's something that I'm not going to guide you specifically on. Overall, it's having in the level of same impact as the US dollar.
Okay. It's all dollar-related ones that's moved, that's created this difference?
Yeah. Yes.
Okay.
It is.
All right. Thank you.
Our next question comes from Maja Pataki from Kepler. Please go ahead.
Yeah, thank you. I actually have just one more question. Everything else has been answered. Lars, would it be possible to give us a bit of an indication on what the impact was from the patent expiry? We just, you know, just get a bit of a feeling of, what the full year impact could be if it doesn't worsen throughout the year.
It's easy to calculate. I think it's zero at this point in time.
Zero. That is o kay. Is there anything upcoming, like tenders or anything, where you think it, you know, that are marking some point in time that could change that?
On catheters or in general?
On catheters. No, impact on, on the catheter side.
Most of the vast majority of the sales or revenue that we have in catheters is reimbursed. It's not, it's not a, it's not a highly tendered business. It's tendered in the Nordics. That's how it's been for the last 15 years, and it just continues to be like that.
What we are going to do is that we are, within this fiscal year, we are going to launch a sort of a well, a bacterial barrier technology product, which is going to be a replacement product, which would means that for people who are with the SpeediCath technology, the SpeediCath straight technology, they will get a significant upgrade of their product for no cost. That's the only thing that we have planned going forward. Will that put us in a better position than the few places where we have tenders? I think so, it's unlikely that they will hit us this year. Or help us this year. It's something that will come in the coming years.
Thank you very much.
Our next question comes from David Adlington from JP Morgan. Please go ahead. Your line is open.
Hey, guys. Thanks for taking the question. Apologies if it's already been asked, but just with respect to the stocking, I just wondered how comfortable you were with your stocking patterns in Wound, because you had a very, very strong Q4 that arguably was the strength there allowed you to hit your full year guidance, and now we've got a big unwind in Q1. I just wondered if you were comfortable where the stocking levels are now, and how any management incentives were paid out on hitting those numbers in Q4? Secondly, just with respect to Wound, if prices for assets are very high, I just wondered if anybody had approached you in terms of possibly divesting your assets. Thanks.
If we look at the stocking, for Wound Care, then, I don't know when you got into the call, but as I explained, What really hits us this quarter is the Greek situation, where we have this price reform. That's very impactful on the numbers that we're looking at. The reason why we had such a strong finish last year was primarily due to the skin, skincare opportunities that we had in the U.S., where one of our big competitors in skincare were closed down by FDA.
Therefore, customers were seeking for a different solution, and that was helping us in that regard. We had no building up of stocks with any of our business partners. That's not what we're seeing. The effect from Greece is so big that if you take Greece out of the numbers, both the comparison numbers and this quarter, then we are in line with the market growth. I don't know if that was what you were searching for?
That's perfect. Yeah, thanks, Lars. That's closes out. Thank you.
All right.
Just on the assets and whether you've been approached to, with potentially disposing your assets?
Well, we have not had those considerations.
Okay, thanks.
Our next question comes from Oliver Metzger from Commerzbank. Please go ahead. Your line is open.
Yeah, hi. Thanks a lot for taking my questions. First question is on the growth in the U.S., which you named basically as quite positive. Could you just comment also on your progress at IDN level, and how far does this have contributed to this strong regional growth? My second question, just should be very easy: Could you just disclose your share of sales within Lilial? Thank you.
Yes, it's an easy question. It's just a matter if you want to talk about it. For the US growth, first of all, we had this stock issue in where we were reducing stock last year in the U.S. That means that we have some very easy comparison numbers this year, and that was to the DKK 270 million. In that sense, we have tailwind this year on the growth for the U.S. Even when we take that out of the numbers, then we are still growing double-digit in the US. Very strong growth, stronger growth than significantly stronger growth than the market.
It comes from a broad source of sources, both from, of course, the direct channel and also from hospitals. We are seeing a very nice pickup in hospitals. That is, of course, in the IDN network, but also in the DPO, where we have, as we've talked about several times, good access. Yes, when it comes to Lilial, maybe you have a comment on that, Anders?
In terms of Lilial and how much it will contribute, we're not disclosing specifically our sales to Lilial, but I mean, or I haven't assumed that Lilial will contribute around 1% on our reported guide in Danish kroner.
Okay. Thank you.
Our next question comes from Christoph Gretler from Credit Suisse. Please go ahead.
Yes, thank you. Hi, Lars. Hi, Anders. Actually, I also had, you know, a question in the same direction with respect to Lilial. Maybe, you know, as a follow-up, you know, could you help me, you know, to understand, you know, what prevented you from bringing innovative products and services to France, you know, before? Why with Lilial, you know, that should help, you know, if I, you know, quote your press release. Also, basically, you mentioned that, you know, you're basically getting more access to payers, you know, also here, you know, could you help me understand why that, you know, is so, you know, important, you know, with respect to the French market in particular?
By the way, you know, I was impressed to see how quickly you got, you know, an acquisition after announcing your strategy, you know, update.
Thank you. We have a very, very strong market shares in France in our business areas. We have also built a patient support program, the Coloplast Care, in the French markets. It is primarily when there are negotiations with the payers, the public payer system in France, it is primarily a conversation between the dealers and the government. It is very obvious that we have different interests, whether you're a manufacturer or whether you are a direct dealer. We wanted to have a better insight to the direct distribution, and we also wanted to have a stronger presence at the seat with the payers.
That is what we are investing for. I would have to say that we have had access to new products in France. We have one of the strongest market shares, one of the strongest market share countries in Europe, in France, so we are very well positioned. Therefore, you can see the French move both as an offensive move but also as a defensive move, because we are fully embracing the value chain in France, and that gives us, of course, a stronger overall position in France, which helps us both to build our position but also to defend what we already have invested in.
It is very, very supplementary to the digital channel that we have built in the French market and helps us to get an even stronger foothold there.
Okay, very clear. Thank you for the clarification.
All right, I think that was the last question. Thank you very much for participating. We're looking forward to seeing all of you in the coming weeks.
This concludes today's call. Thank you.